The Vanguard Group's 13G/A Filing for Vistagen Therapeutics Inc

The Vanguard Group, Inc. filed an amendment to its Schedule 13G for Vistagen Therapeutics Inc, reporting ownership of 1,687,735 shares, representing 5.5% of the company's common stock. The filing indicates that The Vanguard Group holds these shares on behalf of its clients, including investment companies and managed accounts. The shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The Vanguard Group has shared voting power over 179,923 shares and shared dispositive power over 190,732 shares. The filing was signed by Ashley Grim, Head of Global Fund Administration, on October 31, 2025.